



---

Charles Darwin University

## Bird's eye overview of asthma in children

Teoh, Laurel; Chang, Anne B.

*Published in:*  
Indian Journal of Medical Research

*DOI:*  
[10.4103/ijmr.IJMR\\_931\\_21](https://doi.org/10.4103/ijmr.IJMR_931_21)

Published: 01/07/2021

*Document Version*  
Publisher's PDF, also known as Version of record

[Link to publication](#)

*Citation for published version (APA):*  
Teoh, L., & Chang, A. B. (2021). Bird's eye overview of asthma in children. *Indian Journal of Medical Research*, 154(1), 8-11. [https://doi.org/10.4103/ijmr.IJMR\\_931\\_21](https://doi.org/10.4103/ijmr.IJMR_931_21)

### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



## Editorial

### Bird's eye overview of asthma in children

Asthma is a major chronic disease estimated to affect more than 339 million people globally<sup>1</sup>. It imposes a substantial burden to the affected individuals and their families, being the most common non-communicable disease in children. It affects the quality of life (QoL) of affected children and their parents/caregivers, impacting on activity levels, daily functioning, school and work productivity and absenteeism<sup>2,3</sup>. With an increasing prevalence in many regions, the health and economic burden remain substantial.

Asthma is a condition that affects both children and adults. In young children, viral infections particularly rhinovirus infection, can cause recurrent acute asthma exacerbations and/or recurrent wheezing<sup>4</sup>. For many of these children, the recurrent wheezing episodes cease in later childhood but in some, asthma persists. In older children, recurrent asthma exacerbations with chronic interval symptoms on a background of atopy are common. The 'atopic march' starts in infancy as eczema, subsequently as allergic rhinitis and then in later childhood, as asthma<sup>5</sup>. There is a male predominance in childhood asthma. After puberty, females have a higher risk of asthma<sup>6</sup>. In contrast, adults have a more diverse pattern and many have co-existing comorbidities and associations *e.g.*, obesity, gastroesophageal reflux, rhinosinusitis and nasal polyposis and tobacco smoking. Steroid-resistant asthma is more commonly seen in adults than in children<sup>7</sup>. Adult-onset asthma with nasal polyps (eosinophilic type) without atopy is uncommon in children<sup>7</sup>. Severe asthma is rare in preschool children, in contrast to adults, whereby the majority of deaths due to asthma occur in adult-onset asthma.

In the management of childhood asthma, concepts are generally categorized into acute and non-acute asthma. In the non-acute phase, a regular controller/preventer *e.g.*, a low dose inhaled

corticosteroid (ICS) or montelukast should be considered to manage symptoms and reduce the risk of serious exacerbations<sup>8</sup>. Parents or caregivers should be cautioned about the potential adverse neuropsychiatric effects of montelukast. Stepping up treatment in those with persistent symptoms should be considered, after checking inhaler technique, adherence, persistent allergen exposure and addressing comorbidities. Stepping down treatment to the minimum effective dose to maintain good asthma control should subsequently be considered. Suboptimal adherence to controller/preventer medication such as ICS is associated with morbidity and mortality. It can lead to poor clinical outcomes, increased hospitalizations and health care utilization. Poor treatment adherence is thought to be multifactorial. Some of the factors leading to poor treatment adherence are potentially modifiable including access to health care, follow up and medications. Effective monitoring and education can promote treatment adherence. A written personalized asthma action plan should routinely form part of the management plan. Parental/caregivers' beliefs/misconceptions about medication can potentially be modified with ongoing education. Interventions targeting contributing factors may help improve treatment adherence.

The main goal of asthma management should be to achieve and maintain control, *i.e.* to minimize and prevent acute asthma exacerbations, hence reducing the risk of morbidity. Controller/preventer medications include ICS, long-acting beta<sub>2</sub>-agonists with ICS, leukotriene-receptor antagonists, long-acting muscarinic receptor antagonists and in highly selected individuals, monoclonal antibody (biological) agents<sup>9</sup>. The primary goal of asthma control is to use the minimum doses of medications to achieve control of symptoms. Ongoing follow up and monitoring are crucial and treatment may need to be adjusted from time to time. Improved follow up and access to

a physician as well as comprehensive education will likely reduce asthma readmission rates, which will, in turn, reduce the burden on affected individuals, the healthcare system and the economy.

Though asthma is known as a chronic airway problem, the large burden in children with asthma relates to acute/recurrent exacerbations of flare-ups. Acute asthma is one of the most common causes of children presenting to emergency departments<sup>10</sup>. In the USA, 17.2 per cent of children with asthma reported an emergency department or urgent care visit within the past 12 months<sup>11</sup>. Despite the burden of asthma exacerbations, there are relatively little data on the determinants affecting the severity of acute asthma. This is a clinical research gap. Current likely factors include extrinsic determinants (*e.g.*, access to health care and socio-economic influences)<sup>12</sup> and biological factors. Atopy<sup>13,14</sup> and viral infections<sup>4</sup> are likely contributing factors. Up to 80 per cent of children with asthma exacerbations have viral infections detected<sup>4</sup>. Asthma studies in children have described allergic sensitization and risk of hospitalization for acute asthma<sup>15,16</sup>. Viruses together with allergen exposure likely increase the risk of hospitalization with asthma<sup>13,17</sup>. We have shown that the presence of viruses does not appear to impact on asthma recovery but children with atopy appear to be more likely to represent for asthma relapse within 14 days<sup>18</sup>.

Another underappreciated issue in asthma is the morbidity after an acute exacerbation *i.e.*, in the asthma recovery phase where many experience ongoing morbidity<sup>19,20</sup>. Despite significant advances in asthma therapies, research gaps exist and need to be addressed as a priority. There is little research in the recovery phase following asthma exacerbations despite the importance of asthma exacerbations and its burden on affected children and their families<sup>21,22</sup>. In our asthma studies<sup>18,23,24</sup>, we have shown that the morbidity of asthma extends well beyond the immediate acute phase. We used several patient-oriented and validated outcomes in children including the Asthma Diary Scale (ADS)<sup>25</sup> and the Paediatric Asthma Quality of Life Questionnaire<sup>26</sup>, which measure the impairments due to limitations of daily activities and the anxieties/fears of parents/carers due to their child's illness. Other tools available which we used included the validated cough diary scale<sup>27</sup> to measure prolonged cough in the recovery phase in children with asthma exacerbations<sup>23</sup>. The Canadian Acute Respiratory Illness and Flu Scale (CARIFS)<sup>28</sup> is another validated tool that can be used

as a measure of disease severity and burden of illness to the parent/carer in children with acute respiratory infections. We have utilized the CARIFS instrument in asthma studies and found that the CARIFS and ADS scores correlated well as a disease severity measure during the post-asthma exacerbation recovery phase in children<sup>24</sup>.

Much progress has been made in the field of asthma, ranging from mechanisms, treatments and measurement outcomes, but many clinical research gaps remain. There is substantial research into the genetics of asthma susceptibility, severity and response to treatment (pharmacogenetics). Novel molecular targets in the pathogenesis of asthma with the genome-wide association studies have significantly improved our understanding but only a small proportion of the heritability of asthma can be accounted for<sup>29</sup>. Many biomarkers in asthma have been investigated and researched, however, only a few so far are practical and used in clinical practice. Using a panel of biomarkers could improve the identification of asthma phenotypes and endotypes which in turn may predict therapeutic response to biologic treatments<sup>30</sup>. Biomarkers include blood eosinophils, serum IgE, serum periostin, sputum eosinophils and fractional nitric oxide in the exhaled breath (FeNO) but all these have limitations in clinical practice. Unfortunately, an ideal biomarker does not exist currently. In addition, there is research into newer imaging modalities using quantitative computed tomography, which can estimate airway wall thickness and wall area percentages, thereby estimating airway wall remodelling. Air-trapping can also be calculated and together with remodelling, can be correlated with lung function and asthma severity<sup>31</sup>. Biologics for the management of severe asthma such as anti-IgE (omalizumab), anti-interleukin (IL)-5 (mepolizumab, reslizumab and benralizumab), anti-IL-4/IL-13 (dupilumab) and anti-thymic stromal lymphopoietin (tezepelumab) have been shown to reduce asthma exacerbations<sup>32</sup>. These biologics can reduce steroid-associated adverse events in the management of severe asthma.

Current treatments available are highly effective and significant advances have been made in understanding the underlying mechanisms causing asthma. In spite of this, considerable morbidity and mortality exist. Most asthma-related mortality occurs in lower-income countries, and most asthma deaths are preventable<sup>33</sup>. Improving access to health care and medications and education regarding potential exposure to risk factors

would likely reduce morbidity and mortality related to asthma. There is currently no cure for asthma but reducing or preventing asthma exacerbations and optimizing management should be aimed for.

In summary, despite substantial advances in asthma research, considerable clinical research gaps exist. The goals of asthma research should be prevention of its onset, optimization of management including education of risk factors and correct use of delivery devices, treatment adherence, reduction in ongoing morbidity and improvement in the QoL of individuals and their families and ultimately cure of the disease. Governments should concentrate on research, intervention and monitoring with the aim of reducing the burden of asthma globally.

**Conflicts of Interest:** None.

**Laurel Teoh<sup>1,2,3</sup> & Anne B Chang<sup>1,4,5,\*</sup>**

<sup>1</sup>Child Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, <sup>2</sup>Faculty of Medicine, The University of Queensland, <sup>3</sup>Department of Paediatrics, Caboolture Hospital, Caboolture, Queensland 4510, <sup>4</sup>Department of Respiratory & Sleep Medicine, Queensland Children's Hospital, <sup>5</sup>Australian Centre for Health Services Innovation, Queensland University of Technology, Brisbane, Australia

\*For correspondence:  
anne.chang@menzies.edu.au

Received March 30, 2021

## References

- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the global burden of disease study 2016. *Lancet* 2017; *390* : 1211-59.
- Dean BB, Calimlim BC, Sacco P, Aguilar D, Maykut R, Tinkelman D. Uncontrolled asthma: Assessing quality of life and productivity of children and their caregivers using a cross-sectional Internet-based survey. *Health Qual Life Outcomes* 2010; *8* : 96.
- Schmier JK, Manjunath R, Halpern MT, Jones ML, Thompson K, Diette GB. The impact of inadequately controlled asthma in urban children on quality of life and productivity. *Ann Allergy Asthma Immunol* 2007; *98* : 245-51.
- Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. *BMJ* 1995; *310* : 1225-9.
- Bantz SK, Zhu Z, Zheng T. The atopic March: Progression from atopic dermatitis to allergic rhinitis and asthma. *J Clin Cell Immunol* 2014; *5* : 202.
- Wright AL, Stern DA, Kauffmann F, Martinez FD. Factors influencing gender differences in the diagnosis and treatment of asthma in childhood: The Tucson children's respiratory study. *Pediatr Pulmonol* 2006; *41* : 318-25.
- Turner S, Upham JW. Asthma in children and adults – What are the differences and what can they tell us about asthma? *Front Pediatr* 2020 ; *8* : 141.
- National Asthma Council. *Australian asthma handbook: The national guidelines for health professionals*. Available from: <http://www.astmahandbook.org.au>, accessed on March 22, 2021.
- Quirt J, Hildebrand KJ, Mazza J, Noya F, Kim H. Asthma. *Allergy Asthma Clin Immunol* 2018; *14* : 50.
- Kelly AM, Powell C, Kerr D. Snapshot of acute asthma: Treatment and outcome of patients with acute asthma treated in Australian emergency departments. *Intern Med J* 2003; *33* : 406-13.
- Centers for Disease Control and Prevention (CDC). *Child health care utilization*. Available from: [https://www.cdc.gov/asthma/asthmadata/child\\_emergency\\_room.html](https://www.cdc.gov/asthma/asthmadata/child_emergency_room.html), accessed on March 22, 2021.
- Wright RJ, Subramanian SV. Advancing a multilevel framework for epidemiologic research on asthma disparities. *Chest* 2007; *132* : 757S-69S.
- Green RM, Custovic A, Sanderson G, Hunter J, Johnston SL, Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: Case-control study. *BMJ* 2002; *324* : 763.
- Solé D, Camelo-Nunes IC, Wandalsen GF, Melo KC, Naspić CK. Is rhinitis alone or associated with atopic eczema a risk factor for severe asthma in children? *Pediatr Allergy Immunol* 2005; *16* : 121-5.
- Sporik R, Platts-Mills TA, Cogswell JJ. Exposure to house dust mite allergen of children admitted to hospital with asthma. *Clin Exp Allergy* 1993; *23* : 740-6.
- Sarpong SB, Karrison T. Sensitization to indoor allergens and the risk for asthma hospitalization in children. *Ann Allergy Asthma Immunol* 1997; *79* : 455-9.
- Murray CS, Poletti G, Keadze T, Morris J, Woodcock A, Johnston SL, et al. Study of modifiable risk factors for asthma exacerbations: Virus infection and allergen exposure increase the risk of asthma hospital admissions in children. *Thorax* 2006; *61* : 376-82.
- Teoh L, Mackay IM, Van Asperen PP, Acworth JP, Hurwitz M, Upham JW, et al. Presence of atopy increases the risk of asthma relapse. *Arch Dis Child* 2018; *103* : 346-51.
- Stevens MW, Gorelick MH. Short-term outcomes after acute treatment of pediatric asthma. *Pediatrics* 2001; *107* : 1357-62.

20. Johnston NW, Sears MR. Asthma exacerbations. 1: Epidemiology. *Thorax* 2006; *61* : 722-8.
21. Fleming L, Murray C, Bansal AT, Hashimoto S, Bisgaard H, Bush A, *et al.* The burden of severe asthma in childhood and adolescence: Results from the paediatric U-BIOPRED cohorts. *Eur Respir J* 2015; *46* : 1322-33.
22. Ferrante G, La Grutta S. The burden of pediatric asthma. *Front Pediatr* 2018; *6* : 186.
23. Teoh L, Chatfield MD, Acworth JP, McCallum GB, Chang AB. Determinants of cough and caregivers' quality of life in pediatric asthma exacerbations. *Pediatr Pulmonol* 2021; *56* : 371-7.
24. Teoh L, Chatfield MD, Acworth JP, McCallum GB, Chang AB. How does the Canadian acute respiratory illness and flu scale relate to other scales in pediatric asthma exacerbations? *J Asthma* 2021. doi: 10.1080/02770903.2021.1946823.
25. Santanello NC, Barber BL, Reiss TF, Friedman BS, Juniper EF, Zhang J. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. *Eur Respir J* 1997; *10* : 646-51.
26. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in the parents of children with asthma. *Qual Life Res* 1996; *5* : 27-34.
27. Chang AB, Newman RG, Carlin JB, Phelan PD, Robertson CF. Subjective scoring of cough in children: Parent-completed vs. child-completed diary cards vs. an objective method. *Eur Respir J* 1998; *11* : 462-6.
28. Jacobs B, Young NL, Dick PT, Ipp MM, Dutkowski R, Davies HD, *et al.* Canadian acute respiratory illness and flu scale (CARIFS): Development of a valid measure for childhood respiratory infections. *J Clin Epidemiol* 2000; *53* : 793-9.
29. Meyers DA, Bleecker ER, Holloway JW, Holgate ST. Asthma genetics and personalised medicine. *Lancet Respir Med* 2014; *2* : 405-15.
30. Tiotiu A. Biomarkers in asthma: State of the art. *Asthma Res Pract* 2018; *4* : 10.
31. Choi S, Hoffman EA, Wenzel SE, Castro M, Fain S, Jarjour N, *et al.* Quantitative computed tomographic imaging-based clustering differentiates asthmatic subgroups with distinctive clinical phenotypes. *J Allergy Clin Immunol* 2017; *140* : 690-700.e8.
32. Grayson MH, Feldman S, Prince BT, Patel PJ, Matsui EC, Apter AJ. Advances in asthma in 2017: Mechanisms, biologics, and genetics. *J Allergy Clin Immunol* 2018; *142* : 1423-36.
33. Soto-Martínez ME, Soto-Quiros ME, Custovic A. Childhood asthma: Low and middle-income countries perspective. *Acta Med Acad* 2020; *49* : 181-90.